MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03235nam a22005417a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
180818s20182018 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1462-8902 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1111/dom.13162 [doi] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
29364586 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. [Review] |
| 251 ## - Source |
|---|
| Source |
Diabetes, Obesity & Metabolism. 20 Suppl 1:22-33, 2018 02. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Diabetes Obes Metab. 20 Suppl 1:22-33, 2018 02. |
| 253 ## - Journal Name |
|---|
| Journal name |
Diabetes, obesity & metabolism |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2018 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2018 |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2018-08-16 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
AIMS: To review the evolution and advancement of GLP-1 receptor agonist (GLP-1RA) therapy, through the lens of randomised controlled trials, from differentiating characteristics, efficacy, safety, tolerability, and cardiovascular outcomes, to evidence gaps and next steps. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
CONCLUSIONS: Over a decade of clinical studies have established the unique contributions of GLP-1 RAs in the treatment of diabetes. Individual differences between the different GLP-1 RAs, in delivery, pharmacokinetic and clinical effects, exist, allowing for tailored approaches to clinical care. The strength of evidence generated through RCTs, both short-term and long-term studies, will continue to evolve and inform our current paradigms in diabetes care. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Copyright (c) 2018 John Wiley & Sons Ltd. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
METHODS: Clinical review of published phase 3 or later RCT data studying efficacy, safety, and outcomes of approved GLP-1 RA therapies. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
RESULTS: Through a wealth of studies, including both placebo-controlled and active-controlled studies, GLP-1 RAs have demonstrated high glycemic efficacy and ability to facilitate weight loss, with minimal risk of hypoglycemia, potential to restore beta cell function, and evidence for improved cardiovascular outcomes in those at risk. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Diabetes Mellitus/dt [Drug Therapy] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Glucagon-Like Peptide-1 Receptor/ag [Agonists] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Hypoglycemic Agents/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Clinical Trials, Phase III as Topic |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Glucagon-Like Peptide 1/aa [Analogs & Derivatives] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Glucagon-Like Peptide 1/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Glucagon-Like Peptides/aa [Analogs & Derivatives] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Glucagon-Like Peptides/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Immunoglobulin Fc Fragments/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Liraglutide/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Peptides/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Randomized Controlled Trials as Topic |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Recombinant Fusion Proteins/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Treatment Outcome |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Weight Loss/de [Drug Effects] |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Health Research Institute |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Review |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Aroda, Vanita R |
| 790 ## - Authors |
|---|
| All authors |
Aroda VR |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1111/dom.13162">https://dx.doi.org/10.1111/dom.13162</a> |
| Public note |
https://dx.doi.org/10.1111/dom.13162 |
| 858 ## - ORCID |
|---|
| ORCID text |
Aroda, Vanita R |
| Orcid |
<a href="https://orcid.org/0000-0002-7706-4585">https://orcid.org/0000-0002-7706-4585</a> |
| Name |
https://orcid.org/0000-0002-7706-4585 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
